Compare MLCO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | NKTR |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2006 | 1996 |
| Metric | MLCO | NKTR |
|---|---|---|
| Price | $5.32 | $71.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $10.10 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 1.5M | 524.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $5.07 | $27.87 |
| 52 Week High | $10.15 | $109.00 |
| Indicator | MLCO | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 47.52 |
| Support Level | $5.13 | $70.48 |
| Resistance Level | $5.73 | $76.45 |
| Average True Range (ATR) | 0.17 | 2.81 |
| MACD | -0.03 | -0.39 |
| Stochastic Oscillator | 33.83 | 23.74 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.